Department of Radiation Oncology, University of Lubeck, Lubeck, Germany.
Cancer. 2010 Aug 1;116(15):3670-3. doi: 10.1002/cncr.25223.
Based on an analysis of 1852 retrospectively evaluated patients with metastatic spinal cord compression (MSCC), a scoring system was developed to predict survival. This study was performed to validate the scoring system in a new data set.
The score included 6 prognostic factors: tumor type, interval between tumor diagnosis and MSCC, other bone or visceral metastases, ambulatory status, and duration of motor deficits. Scores ranged between 20 and 45 points, and patients were initially divided into 5 groups: those with 20 to 25 points, those with 26 to 30 points, those with 31 to 35 points, those with 36 to 40 points, and those with 41 to 45 points. To facilitate the clinical use of the score, the patients were regrouped into 3 groups: those with 20 to 30 points, those with 31 to 35 points, and those with 36 to 45 points. In this study, data of 439 new patients were included who were divided into the same prognostic groups as in the preceding study.
In this study, the 6-month survival rates were 7% (for those with 20-25 points), 19% (for those with 26-30 points), 56% (for those with 31-35 points), 73% (for those with 36-40 points), and 90% (for those with 41-45 points), respectively (P<.0001). After regrouping, the 6-month survival rates were 14% (for those with 20-30 points), 56% (for those with 31-35 points), and 80% (for those with 36-45 points), respectively, in this study (P<.0001).
In the current study, the difference in 6-month survival between the prognostic groups was found to be as significant as in the preceding study. Thus, this scoring system was considered valid to estimate survival of MSCC patients. The system could have been simplified by including only 3 instead of 5 prognostic groups.
基于对 1852 例回顾性评估的转移性脊髓压迫症(MSCC)患者的分析,开发了一种评分系统来预测生存率。本研究旨在新数据集验证评分系统。
该评分包括 6 个预后因素:肿瘤类型、肿瘤诊断与 MSCC 之间的时间间隔、其他骨骼或内脏转移、活动状态以及运动功能障碍持续时间。评分范围为 20 至 45 分,患者最初分为 5 组:20 至 25 分组、26 至 30 分组、31 至 35 分组、36 至 40 分组和 41 至 45 分组。为便于临床应用评分,将患者重新分为 3 组:20 至 30 分组、31 至 35 分组和 36 至 45 分组。在本研究中,纳入了 439 例新患者的数据,这些患者被分为与前一项研究相同的预后组。
在本研究中,6 个月的生存率分别为 7%(20-25 分组)、19%(26-30 分组)、56%(31-35 分组)、73%(36-40 分组)和 90%(41-45 分组)(P<.0001)。重新分组后,本研究中 6 个月的生存率分别为 14%(20-30 分组)、56%(31-35 分组)和 80%(36-45 分组)(P<.0001)。
在本研究中,预后组之间 6 个月生存率的差异与之前的研究一样显著。因此,该评分系统被认为可用于估计 MSCC 患者的生存率。通过仅包括 3 个而不是 5 个预后组,可以简化该系统。